menu
    • menu

    Company profile for Neurimmune

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into antibody therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai. Aducanumab is a human monoclonal antibody removing beta amyloid in brains of pat...
    Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into antibody therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai. Aducanumab is a human monoclonal antibody removing beta amyloid in brains of patients with Alzheimer’s disease. Based on large Phase 3 study results showing clinical benefit, Biogen plans regulatory filing for aducanumab in Alzheimer’s disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeurimmuneSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Wagistrasse 13 CH-8952 Schlieren-Zurich
    Telephone
    Telephone
    +41 44 755 46 59
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurimmune.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/neurimmune
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Al-S Pharma Reports Positive Phase 2 Results for AP-101 in ALS
    Al-S Pharma Reports Positive Phase 2 Results for AP-101 in ALS

    04 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/al-s-pharma-announces-positive-topline-results-from-phase-2-study-of-ap-101-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-302545686.html

    PR NEWSWIRE
    04 Sep 2025
    Share Share
    Neurimmune to regain rights to brain amyloid depleter for Alzheimer™s disease
    Neurimmune to regain rights to brain amyloid depleter for Alzheimer™s disease

    31 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/31/2821023/0/en/Neurimmune-to-regain-global-rights-to-brain-amyloid-depleter-for-the-treatment-of-Alzheimer-s-disease.html

    GLOBENEWSWIRE
    31 Jan 2024
    Share Share
    Neurimmune to preset results of phase 1b proof-of-concept study of NI006
    Neurimmune to preset results of phase 1b proof-of-concept study of NI006

    19 May 2023

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=158207&sid=2

    PHARMABIZ
    19 May 2023
    Share Share
    Biogen CEO points to risk in neuroscience as 3 programs cut
    Biogen CEO points to risk in neuroscience as 3 programs cut

    21 Jul 2022

    // Annalee Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/biogen-ceo-michel-vounatsos-points-inherent-risk-neuroscience-3-programs-cut

    Annalee Armstrong FIERCEBIOTECH
    21 Jul 2022
    Share Share
    AstraZeneca, Swiss firm Neurimmune ink $760 million deal for antibody drug
    AstraZeneca, Swiss firm Neurimmune ink $760 million deal for antibody drug

    01 Mar 2022

    // Pushkala Aripaka REUTERS

    https://www.reuters.com/world/uk/astrazeneca-inks-760-mln-deal-with-swiss-firm-neurimmune-antibody-drug-2022-03-01/

    Pushkala Aripaka REUTERS
    01 Mar 2022
    Share Share
    Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
    Neurimmune expands drug discovery collaboration with Ono Pharmaceutical

    17 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurimmune-expands-drug-discovery-collaboration-with-ono-pharmaceutical-in-the-field-of-neurodegenerative-diseases-301461904.html

    PRNEWSWIRE
    17 Jan 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search